{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:55:09Z","timestamp":1793130909165,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijantimicag.2025.107696","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T16:19:52Z","timestamp":1766420392000},"page":"107696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"Digbijay","family":"Kunwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8089-1592","authenticated-orcid":false,"given":"Itay","family":"Zahavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Olchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagar","family":"Dallasheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2317-1112","authenticated-orcid":false,"given":"Mical","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107696_bib0001","unstructured":"Pyelonephritis (acute): antimicrobial prescribing. NICE guideline. Reference number: NG111. Published: 31 October 2018. Available at: https:\/\/www.nice.org.uk\/guidance\/ng111. Last accessed 7 January, 2026."},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European association of urology guidelines on urological infections: summary of the 2024 Guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0003","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jiac.2022.05.008","article-title":"AAUS guideline for acute uncomplicated pyelonephritis","volume":"28","author":"Shigemura","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0004","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.44495","article-title":"Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement","volume":"7","author":"Nelson","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib64","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib65","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0006","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jiac.2024.05.001","article-title":"Efficacy of carbapenems and alternative antimicrobials for treating complicated urinary tract infections caused by third-generation cephalosporin-resistant gram-negative bacteria: a systematic review and meta-analysis of randomised controlled trials","volume":"30","author":"Maeda","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0007","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018769","article-title":"Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection: A systematic review and network meta-analysis","volume":"99","author":"Tan","year":"2020","journal-title":"Med Baltim"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0008","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jinf.2020.08.008","article-title":"Carbapenem-alternative strategies for complicated urinary tract infections: a systematic review of randomized controlled trials","volume":"81","author":"Ten Doesschate","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0009","doi-asserted-by":"crossref","first-page":"ofaa480","DOI":"10.1093\/ofid\/ofaa480","article-title":"Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: a systematic review and meta-analysis","volume":"9","author":"Ezure","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106830","article-title":"Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Hung","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0011","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0214","article-title":"Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis","volume":"14","author":"Wagenlehner","year":"2025","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0012","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.319.7203.185","article-title":"Understanding controlled trials: baseline imbalance in randomised controlled trials","volume":"319","author":"Roberts","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0013","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5.","article-title":"Chapter 8: Assessing risk of bias in a randomized trial","author":"Higgins","year":"2024"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0015","series-title":"Cochrane handbook for systematic reviews of interventions version 6.5","article-title":"Chapter 14: Completing \u2018summary of findings\u2019 tables and grading the certainty of the evidence","author":"Sch\u00fcnemann","year":"2024"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0016","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0017","article-title":"Analysing data and undertaking meta-analyses. 10.10.2 Identifying and measuring heterogeneity","author":"Deeks","year":"2024","journal-title":"Cochrane handbook for systematic reviews of interventions version 6.5"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0018","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF01640830","article-title":"Mecillinam versus cephaloridine for the treatment of acute pyelonephritis","volume":"10","author":"Trollfors","year":"1982","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/12.suppl_A.47","article-title":"A comparison of ceftazidime and tobramycin in the treatment of complicated urinary tract infections","volume":"12","author":"Cox","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0020","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0022-5347(17)51467-6","article-title":"Ceftazidime, a new cephalosporin in the treatment of complicated urinary tract infections: a comparative study with tobramycin","volume":"130","author":"Frimodt-M\u00f8ller","year":"1983","journal-title":"J Urol"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0021","first-page":"337","article-title":"Intravenous mecillinam, trimethoprim and ampicillin in acute pyelonephritis","volume":"9","author":"Ode","year":"1983","journal-title":"Drugs under Experimen Clinical Res"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0022","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0140-6736(84)91817-8","article-title":"Aztreonam compared with gentamicin for treatment of serious urinary tract infections","volume":"1","author":"Sattler","year":"1984","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0023","first-page":"459","article-title":"Comparison of netilmicin with ceftriaxone for the treatment of severe or complicated urinary tract infections","volume":"99","author":"Bailey","year":"1986","journal-title":"N Z Med J"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0024","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/00365548609032360","article-title":"The combination of pivampicillin and pivmecillinam versus pivampicillin alone in the treatment of acute pyelonephritis","volume":"18","author":"Eriksson","year":"1986","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0025","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0090-4295(87)90058-6","article-title":"Clinical comparison of piperacillin and cefamandole in treatment of complicated urinary tract infections","volume":"29","author":"Resnick","year":"1987","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0026","doi-asserted-by":"crossref","first-page":"157S","DOI":"10.1016\/0002-9343(89)90048-X","article-title":"Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections","volume":"87","author":"Cox","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0027","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01973737","article-title":"Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis","volume":"9","author":"Sandberg","year":"1990","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0028","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/26.suppl_D.93","article-title":"Comparison of i.v. ofloxacin and piperacillin in the treatment of complicated urinary tract infections","volume":"26","author":"Schalkh\u00e4user","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0029","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0090-4295(90)80074-W","article-title":"Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole","volume":"35","author":"Seidmon","year":"1990","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.35.9.1849","article-title":"Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study","volume":"35","author":"Fang","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0031","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/infdis\/163.2.325","article-title":"Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days","volume":"163","author":"Johnson","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9343(92)90614-H","article-title":"Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis","volume":"92","author":"Hyslop","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/0002-9343(92)90316-4","article-title":"A multicenter study of lomefloxacin and trimethoprim\/sulfamethoxazole in the treatment of uncomplicated acute pyelonephritis","volume":"92","author":"Mouton","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0034","doi-asserted-by":"crossref","unstructured":"Harding G, Nicolle L, Wenman W, Richards G, Louie T, Martel A, et al. Randomised comparison of oral ciprofloxacin vs standard parenteral therapy in the treatment of complicated urinary tract infections 1993;46:333\u20134.","DOI":"10.2165\/00003495-199300453-00130"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0035","doi-asserted-by":"crossref","unstructured":"Louie TJ. Comparison of lomefloxacin and cotrimoxazole in the treatment of complicated urinary tract infections 1993;45:345\u20137.","DOI":"10.2165\/00003495-199300453-00137"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0036","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1128\/AAC.38.6.1368","article-title":"Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole","volume":"38","author":"Nicolle","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0037","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S0399-077X(05)81362-9","article-title":"Use of ceftazidime at the initial posology 1 g twice daily in the empiric treatment of nosocomial urinary tract infections following urinary tract surgery: comparison with ciprofloxacine","volume":"25","author":"Botto","year":"1995","journal-title":"Med et maladies infect"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0038","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/00365549509047047","article-title":"Ampicillin plus mecillinam vs. cefotaxime\/cefadroxil treatment of patients with severe pneumonia or pyelonephritis: a double-blind multicentre study evaluated by intention-to-treat analysis","volume":"27","author":"Cronberg","year":"1995","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0149-2918(95)80114-6","article-title":"Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection","volume":"17","author":"Gottlieb","year":"1995","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9343(96)00112-X","article-title":"Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections","volume":"100","author":"Sharifi","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0041","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0042","first-page":"29","article-title":"Cefpodoxime proxetil therapy in patients with acute uncomplicated pyelonephritis","volume":"10","author":"Naber","year":"2001","journal-title":"Chemo J"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0090-4295(02)01664-3","article-title":"A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults","volume":"60","author":"Jimenez-Cruz","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0044","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1128\/AAC.46.9.2895-2900.2002","article-title":"Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"46","author":"Tomera","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0045","doi-asserted-by":"crossref","unstructured":"Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis 2009;53:3782\u201392. https:\/\/doi.org\/10.1128\/AAC.00837-08.","DOI":"10.1128\/AAC.00837-08"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0046","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3346\/jkms.2012.27.5.476","article-title":"Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial","volume":"27","author":"Park","year":"2012","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0047","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0048","doi-asserted-by":"crossref","unstructured":"Connolly LE, Riddle V, Cebrik D, Armstrong ES, Miller LG. A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis 2018;62. https:\/\/doi.org\/10.1128\/AAC.01989-17.","DOI":"10.1128\/AAC.01989-17"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0049","doi-asserted-by":"crossref","unstructured":"Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, et al. Once-daily plazomicin for complicated urinary tract infections 2019;380:729\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1801467.","DOI":"10.1056\/NEJMoa1801467"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0050","doi-asserted-by":"crossref","unstructured":"Lojanapiwat B, Nimitvilai S, Bamroongya M, Jirajariyavej S, Tiradechavat C, Malithong A, et al. Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial 2019;12:173\u201381. https:\/\/doi.org\/10.2147\/IDR.S178183.","DOI":"10.2147\/IDR.S178183"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0051","doi-asserted-by":"crossref","unstructured":"Belley A, Barth P, Kashyap S, Lahlou O, Motta P, Knechtle P, et al. Cefepime-enmetazobactam demonstrates superiority to piperacillin-tazobactam in a subgroup of patients with complicated urinary tract infections\/acute pyelonephritis caused by extended spectrum \u03b2-lactamase-producing enterobacterales 2020;7:S845. https:\/\/doi.org\/10.1093\/ofid\/ofaa515.1901.","DOI":"10.1093\/ofid\/ofaa515.1901"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0052","doi-asserted-by":"crossref","unstructured":"Tehrani S, Elyasi F, Abolghasemi S. Levofloxacin versus ceftriaxone for the treatment of acute pyelonephritis in Iranian adults 2021;21:603\u2013607. https:\/\/doi.org\/10.2174\/1871526520999200727154214.","DOI":"10.2174\/1871526520999200727154214"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/S0002-9343(20)31151-7","article-title":"Comparison of intravenous fleroxacin with ceftazidime for treatment of complicated urinary tract infections","volume":"94","author":"Cox","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0054","doi-asserted-by":"crossref","unstructured":"Preheim LC, Childs SJ, Rajfer J, Bittner MJ. Randomized, double-blind comparison of cefepime and ceftazidime therapy for urinary tract infection 1995;56:729\u201337. https:\/\/doi.org\/10.1016\/0011-393X(95)85056-2.","DOI":"10.1016\/0011-393X(95)85056-2"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0055","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1007\/s10096-018-3371-y","article-title":"A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis","volume":"37","author":"Cattrall","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0056","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.cmi.2022.10.004","article-title":"Highly versus less bioavailable oral antibiotics in the treatment of gram-negative bloodstream infections: a propensity-matched cohort analysis","volume":"29","author":"Mponponsuo","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0057","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1093\/jac\/dkaa369","article-title":"Effectiveness and safety of an institutional aminoglycoside-based regimen as empirical treatment of patients with pyelonephritis","volume":"75","author":"Elbaz","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0058","unstructured":"European Centre For Disease Prevention And Control. Antimicrobial resistance in the EU\/EEA (EARS-Net) - annual epidemiological report 2023. Stockholm: ECDC; 2024."},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0059","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Reference Number: CPMP\/EWP\/558\/95 Rev 3. Legal effective date: 01\/12\/2022. Avaiable at: https:\/\/www.ema.europa.eu\/en\/evaluation-medicinal-products-indicated-treatment-bacterial-infections-scientific-guideline. Last accessed 7 January, 2026."},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0060","unstructured":"U. S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry. Docket Number: FDA-2012-D-0148 2018. June 2018. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/complicated-urinary-tract-infections-developing-drugs-treatment. Last accessed 7 January, 2026."},{"key":"10.1016\/j.ijantimicag.2025.107696_bib66","article-title":"Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0061","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/cid\/ciad010","article-title":"Discordant clinical and microbiological outcomes are associated with late clinical relapse in clinical trials for complicated urinary tract infections","volume":"76","author":"Kadry","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107696_bib0062","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/ciae050","article-title":"Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone-nonsusceptible escherichia coli or klebsiella pneumoniae bloodstream infections: post hoc insights from the MERINO trial","volume":"78","author":"Hardy","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925002511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:24:50Z","timestamp":1770985490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925002511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0924857925002511"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107696","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107696"}}